RELMADA THERAPEUTICS, INC. Deferred Offering Costs
RELMADA THERAPEUTICS, INC. (RLMD) had Deferred Offering Costs of $42.73 million as of 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2023-03-23
- 2022-12-31: Deferred Offering Costs $42.73M.
- 2020-05-15: Deferred Offering Costs $75.00M.
- 2014-03-31: Deferred Offering Costs $45.50K.
| Period end | Deferred Offering Costs |
|---|---|
| 2022-12-31 | $42.73M 10-K · filed 2023-03-23 |
| 2020-05-15 | $75.00M 10-K · filed 2021-03-24 |
| 2014-03-31 | $45.50K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |